IASO Bio’s in vivo CAR-T IASO208 receives FDA clinical trial clearance
September 17, 2026
Source: drugdu
33
On September 16, IASO Biotherapeutics announced that its investigational new drug application for IASO208, a CD20-targeting in vivo CAR-T product developed on its proprietary InTelliCAR platform, has received FDA clearance in the U.S.
As the first lentiviral vector-based in vivo CAR-T product from China to receive FDA IND clearance, IASO208 will directly proceed to a Phase Ib study based on Chinese investigator-initiated trial data, targeting relapsed/refractory B-cell non-Hodgkin lymphoma.
In vivo CAR-T is a next-generation cell therapy technology that eliminates the need for ex vivo T cell engineering, instead delivering vectors directly in patients to generate CAR-T cells in vivo. This approach has the potential to dramatically reduce treatment costs and timelines, moving cell therapy toward "off-the-shelf."
The FDA clearance for IASO208 signifies that China is competing on par with the international community in the in vivo CAR-T space, further deepening IASO Biotherapeutics' internationalization in cell therapy.
Source: http://m.toutiao.com/group/7686078944797311529/
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Novartis acquires Sironax’s blood-brain barrier delivery platform for $125 million September 17, 2026
- NMPA accepts marketing registration application for Velsipity domestic manufacturing transfer September 17, 2026
- Ziprasidone mesylate from SSY Group has been approved for registration as an active pharmaceutical ingredient. September 17, 2026
- Kanghong Pharmaceutical’s research on Shugan Jieyu Capsules won the first prize of the Science and Technology Award of the Chinese Pharmaceutical Association. September 17, 2026
- Johnson & Johnson celebrates the launch of Rybrevant FASPRO (amivantamab subcutaneous injection) in China September 17, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
